Zhaoliang Su
- Immunology top 2%
- IL-33, ST2, and ILC Pathways 22
- Immune Response and Inflammation 18
- Immune Cell Function and Interaction 16
- Immune cells in cancer 12
- Clinical Biochemistry top 1%
- Advanced Glycation End Products research 22
- Cancer Research top 5%
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria 11
- Oncology top 5%
-
- Cardiac Fibrosis and Remodeling 11
-
- Eosinophilic Esophagitis 10
Zhaoliang Su
151 papers receiving 3.6k citations
Peers
Comparison fields: 5 of 124
- Immunology 1.4k
- Clinical Biochemistry 413
- Cancer Research 498
- Molecular Medicine 145
- Oncology 564
Countries citing papers authored by Zhaoliang Su
This map shows the geographic impact of Zhaoliang Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhaoliang Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhaoliang Su more than expected).
Fields of papers citing papers by Zhaoliang Su
This network shows the impact of papers produced by Zhaoliang Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhaoliang Su. The network helps show where Zhaoliang Su may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zhaoliang Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 7 | |
| 5 | 2024 | 8 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 3 | |
| 8 | 2023 | 12 | |
| 9 | 2023 | 10 | |
| 10 | 2023 | 3 | |
| 11 | 2022 | 17 | |
| 12 | 2021 | 33 | |
| 13 | 2021 | 12 | |
| 14 | 2020 | 56 | |
| 15 | 2017 | 2 | |
| 16 | 2012 | 47 | |
| 17 | Drug resistance and transposon and insertion sequence of multi-drug resistant Acinetobacter baumannii. | 2010 | 1 |
| 18 | 2010 | 20 | |
| 19 | 2009 | 83 | |
| 20 | Isolation and Identification of Flocculant-producing Pseudomonas sp.and Study on Properties of Flocculant | 2008 | 1 |
About Zhaoliang Su
Zhaoliang Su is a scholar working on Immunology, Clinical Biochemistry and Molecular Medicine, having authored 159 papers that have together received 3.7k indexed citations. Recurring topics across this work include IL-33, ST2, and ILC Pathways (22 papers), Advanced Glycation End Products research (22 papers), Immune Response and Inflammation (18 papers), Immune Cell Function and Interaction (16 papers), Immune cells in cancer (12 papers), Antibiotic Resistance in Bacteria (11 papers), Cardiac Fibrosis and Remodeling (11 papers) and Eosinophilic Esophagitis (10 papers). The work is most often cited by research in Immunology (1.4k citations), Clinical Biochemistry (413 citations) and Cancer Research (498 citations). Zhaoliang Su has collaborated with scholars based in China, Canada and Hong Kong. Frequent co-authors include Huaxi Xu, Shengjun Wang, Haitao Zhu, Prince Amoah Barnie, Yanfang Liu, Jie Wan, Jianguo Chen, Dinesh Kumar Kesavan, Wei Cai and Zheng Dong. Their work appears in journals such as PLoS ONE, Scandinavian Journal of Immunology, International Immunopharmacology, Journal of Leukocyte Biology and BioMed Research International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.